Pfizer and BioNTech Announce New Agreement with U.S. Government to Provide Additional Doses of COVID-19 Vaccine
June 29, 2022 16:45 ET
|
BioNTech SE
105 million 30 µg, 10 µg and 3 µg doses to be delivered into Q4 2022, with an option for the U.S. Government to purchase up to 195 million additional doses NEW YORK and MAINZ, GERMANY, JUNE...
Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron
June 25, 2022 10:02 ET
|
BioNTech SE
Omicron-adapted monovalent candidate given as a fourth booster dose elicited a 13.5 and 19.6-fold increase in neutralizing geometric titers against Omicron BA.1 at 30 µg and 60 µg dose levels;...
Aeterna Zentaris Announces Results of Annual Meeting of Shareholders
June 21, 2022 16:01 ET
|
Aeterna Zentaris Inc
- Vote to approve share consolidation adjourned to July 6, 2022 TORONTO, ONTARIO, June 21, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a...
Pfizer und BioNTech erhalten FDA-Notfallzulassung für ihren COVID-19-Impfstoff bei Kindern im Alter von 6 Monaten bis 4 Jahren
June 17, 2022 09:22 ET
|
BioNTech SE
Daten einer klinischen Phase-2/3-Studie zeigten, dass der Pfizer-BioNTech COVID-19-Impfstoff in dieser Altersgruppe eine starke Immunantwort auslöstDie Impfserie mit drei 3-µg-Dosen bei Kindern im...
Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age
June 17, 2022 09:22 ET
|
BioNTech SE
In a Phase 2/3 clinical trial, the Pfizer-BioNTech COVID-19 Vaccine elicited a strong immune response in this age group Three 3-µg doses had favorable safety profile similar to placebo in young...
Aditxt Engages IBN (InvestorBrandNetwork) To Bolster Its Corporate Communications Efforts
June 09, 2022 08:30 ET
|
InvestorBrandNetwork (IBN)
LOS ANGELES, June 09, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – Aditxt, Inc. (“Aditxt” or “the Company”) (NASDAQ: ADTX), a biotech innovation company, today announces it has selected the corporate...
Pardes Biosciences to Present at Jefferies Global Healthcare Conference
June 01, 2022 08:30 ET
|
Pardes Biosciences, Inc
CARLSBAD, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone novel...
Pfizer-BioNTech COVID-19-Impfstoff zeigt bei Kindern im Alter von 6 Monaten bis unter 5 Jahren nach drei Dosen starke Immunantworten, hohe Wirksamkeit und vorteilhaftes Sicherheitsprofil
May 23, 2022 06:45 ET
|
BioNTech SE
Basierend auf den ersten Studiendaten erfüllen drei Dosen des Pfizer-BioNTech COVID-19-Impfstoffs alle für die US-Notfallzulassung notwendigen Immunobridging-Kriterien (Vergleich der...
Pfizer-BioNTech COVID-19 Vaccine Demonstrates Strong Immune Response, High Efficacy and Favorable Safety in Children 6 Months to Under 5 Years of Age Following Third Dose
May 23, 2022 06:45 ET
|
BioNTech SE
Based on topline data, three doses of the Pfizer-BioNTech COVID-19 Vaccine met all immunobridging criteria required for Emergency Use AuthorizationThe third 3-µg dose was well-tolerated among 1,678...
ProPhase Labs Announces Record First Quarter 2022 Financial Results
May 13, 2022 08:30 ET
|
ProPhase Labs, Inc.
Record Net Revenues of $47.5 Million, Up 211% Year-over-Year Record Net Income of $12.5 Million, Increasing 1082% Year-over-Year Announces Special Cash Dividend of $0.30 per...